US pharma giant Pfizer on Saturday announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...

Tuesday Pfizer announced it's expanding its clinical trials for younger children ages 5 to 11-years-old. Medical doctors are calling this the final frontier. This is a 2-year study, where a subset of ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Vaccine maker Pfizer said Friday that trials of its vaccine in children ages 2 to 5 show that it did not provide the expected immunity in kids this age, and it is adding a third dose to the regimen.